Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient (API) ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.
The API is used as an ingredient for anesthetics.
The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.
The company's shares rose over 1% during midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.